Dear Radiation Oncology Insider,
This edition of the Radiation Oncology Insider brings you the latest news in prostate cancer treatment. In our Insider Exclusive story, Dr. Howard Sandler from the University of Michigan Medical Center in Ann Arbor asks and answers the question: How much androgen deprivation therapy (ADT) is enough? Click here to learn more.
In other prostate cancer research, we report on the final results of two major trials. One multi-institutional study looked at ADT, radiotherapy, and comorbidities, while another detailed the outcome of dose escalation. You can read about both papers by clicking here. Also, find out what treatment course is best for men with rapidly rising prostate-specific antigen (PSA) levels.
Next we tackle the topic of extracapsular extension of prostate tumors identified by MRI, which can be a predictor of metastatic recurrence following radiation therapy, according to researchers from the University of California, San Francisco. Learn more about their research by clicking here.
Another recent study found that survivors of cancer have lower compliance rates for cancer-related screenings as oncologists become less involved in their care. Getting oncologists more involved in a patient's care after they've survived a bout with cancer could be the cure to this dilemma, according to an article you can reach by clicking here.
Finally, radiation therapy for breast cancer is the subject of two recent stories, one on how a shorter course of radiation can be both safe and effective and produce a lower overall dose, while a second study describes how accelerated partial-breast brachytherapy is turning to directional radiation sources to lower radiation toxicity to the skin and chest wall.
